Application of calibrated fMRI in Alzheimer's disease

Autor: Sylvie Belleville, Serge Gauthier, Douglas L. Arnold, Oury Monchi, Marie-Jeanne Kergoat, Isabelle Lajoie, Felipe B. Tancredi, Julien Doyon, Howard Chertkow, Richard D. Hoge, Pierre Bellec, Yan Deschaintre, Scott Nugent, Clément Debacker, Kenneth S. Dyson, Christian Bocti, AmanPreet Badhwar
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Male
Cognitive Neuroscience
BOLD calibration constant
Precuneus
Grey matter
lcsh:Computer applications to medicine. Medical informatics
lcsh:RC346-429
030218 nuclear medicine & medical imaging
03 medical and health sciences
0302 clinical medicine
Functional neuroimaging
Alzheimer Disease
medicine
Dementia
Humans
Radiology
Nuclear Medicine and imaging
Cerebrovascular reactivity
lcsh:Neurology. Diseases of the nervous system
Aged
Aged
80 and over
medicine.diagnostic_test
Functional Neuroimaging
Magnetic resonance imaging
Regular Article
Alzheimer's disease
Cerebral blood flow
medicine.disease
Magnetic Resonance Imaging
3. Good health
Oxygen
medicine.anatomical_structure
Neurology
Calibrated fMRI
Cerebrovascular Circulation
Calibration
lcsh:R858-859.7
Oxidative metabolism
Female
Spin Labels
Neurology (clinical)
Oxygen extraction fraction
Occipital lobe
Psychology
Neuroscience
030217 neurology & neurosurgery
Zdroj: NeuroImage : Clinical
NeuroImage: Clinical, Vol 15, Iss, Pp 348-358 (2017)
ISSN: 2213-1582
Popis: Calibrated fMRI based on arterial spin-labeling (ASL) and blood oxygen-dependent contrast (BOLD), combined with periods of hypercapnia and hyperoxia, can provide information on cerebrovascular reactivity (CVR), resting blood flow (CBF), oxygen extraction fraction (OEF), and resting oxidative metabolism (CMRO2). Vascular and metabolic integrity are believed to be affected in Alzheimer's disease (AD), thus, the use of calibrated fMRI in AD may help understand the disease and monitor therapeutic responses in future clinical trials. In the present work, we applied a calibrated fMRI approach referred to as Quantitative O2 (QUO2) in a cohort of probable AD dementia and age-matched control participants. The resulting CBF, OEF and CMRO2 values fell within the range from previous studies using positron emission tomography (PET) with 15O labeling. Moreover, the typical parietotemporal pattern of hypoperfusion and hypometabolism in AD was observed, especially in the precuneus, a particularly vulnerable region. We detected no deficit in frontal CBF, nor in whole grey matter CVR, which supports the hypothesis that the effects observed were associated specifically with AD rather than generalized vascular disease. Some key pitfalls affecting both ASL and BOLD methods were encountered, such as prolonged arterial transit times (particularly in the occipital lobe), the presence of susceptibility artifacts obscuring medial temporal regions, and the challenges associated with the hypercapnic manipulation in AD patients and elderly participants. The present results are encouraging and demonstrate the promise of calibrated fMRI measurements as potential biomarkers in AD. Although CMRO2 can be imaged with 15O PET, the QUO2 method uses more widely available imaging infrastructure, avoids exposure to ionizing radiation, and integrates with other MRI-based measures of brain structure and function.
Highlights • An advanced calibrated fMRI method is employed to explore brain physiology in AD. • A pattern of hypoperfusion and hypometabolism was observed as in PET studies. • The method provides several potential biomarkers of interest in AD. • The technique may help by providing new insights into the pathophysiology of AD.
Databáze: OpenAIRE
Externí odkaz: